Zepbound vs Mounjaro — same molecule, insurance headache explained

I work in healthcare benefits administration. This is extremely common and here's why: Most employer plans specifically exclude "anti-obesity medications" (AOMs) as a carve-out. This applies to Zepbound, Wegovy, Contrave, etc. It's a cost-containment measure because: - AOMs are expensive ($1,000-1,500/month) - The eligible population is massive (42% of US adults are obese) - Plans can't absorb that cost BUT those same plans cover diabetes medications because diabetes treatment is considered medically necessary, not elective. Mounjaro and Zepbound are the same molecule (tirzepatide) but carry different NDC numbers and different FDA-approved indications. The PBM (pharmacy benefit manager) processes them differently. Your doctor found the workaround. It's technically legitimate if she genuinely believes you have early T2DM. A1C 6.4% is on the doorstep.

PCP here. I do this literally every day. The current insurance landscape forces us to play diagnostic gymnastics to get our patients medications they need. Some strategies I use: 1. A1C 6.0-6.4%: Document as "prediabetes with high risk of progression" → Mounjaro 2. A1C ≥ 6.5%: Straightforward T2DM diagnosis → Mounjaro 3. A1C 5.7-5.9% + obesity: Try Zepbound first, if denied → document metabolic syndrome components → appeal I don't love this system. I shouldn't have to justify treating a disease (obesity) by diagnosing a different disease. But here we are. > She documented it as "early type 2 diabetes" Your doctor is advocating for you. That's a good doctor.

I'll say the quiet part out loud: isn't this just... insurance fraud? If the diagnosis is prediabetes (6.4%) and the doctor codes it as T2DM to get coverage, that's a false claim, right? Not judging — I think the system is broken too — but I want to understand the legal/ethical implications. Especially for the doctor.

It's a gray area. The ADA itself acknowledges that the A1C threshold of 6.5% for T2DM is somewhat arbitrary and that prediabetes and early T2DM exist on a continuum. An A1C of 6.4% with metabolic syndrome, family history, and clinical judgment CAN be legitimately diagnosed as early T2DM. ICD-10 codes: - E11.9 = T2DM without complications - R73.03 = Prediabetes - E11.65 = T2DM with hyperglycemia A doctor using clinical judgment to place a patient at 6.4% into E11.9 instead of R73.03 isn't necessarily fraudulent — it's a clinical decision. But coding specifically to obtain coverage rather than reflecting genuine clinical assessment? That's where it gets ethically murky. I document my clinical reasoning extensively. If audited, I can defend every diagnosis.